7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
July 2025 in “Journal of Investigative Dermatology” Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
June 2026 in “International Journal of Innovative Technologies in Social Science” Low-dose oral minoxidil is effective and safe for treating male pattern baldness.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
June 2026 in “British Journal of Dermatology” The treatment effectively improved hair growth and was well tolerated in most men.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
September 2025 in “Journal of the American Academy of Dermatology” 3 citations
,
April 2012 in “Journal of the American Academy of Dermatology” Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
16 citations
,
March 2022 in “Journal of Clinical Medicine” Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
31 citations
,
April 2016 in “Journal of the American Academy of Dermatology” Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.
May 2017 in “Journal of The American Academy of Dermatology” The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.
February 2024 in “Skin research and technology” LC-OCT is a promising tool for diagnosing and monitoring Alopecia areata.
1 citations
,
July 2024 in “JAAD International” Low-dose oral minoxidil is effective for alopecia even with other medications.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
1 citations
,
December 2023 in “Value in Health” The EQ-5D does not fully capture the impact of alopecia areata on quality of life.
8 citations
,
April 1991 in “European journal of endocrinology” 3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.
July 2026 in “Journal of the American Academy of Dermatology” 2 citations
,
August 2024 in “JAAD International” Combining low-dose oral minoxidil and spironolactone may improve hair growth safely.
The new gel for hair loss is safe, effective, and reduces side effects.
January 2013 in “Annals of King Edward Medical University” Androgenetic alopecia negatively impacts quality of life, especially for women, due to social reactions.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
September 2025 in “AESTHETIC OROFACIAL SCIENCE” PDO threads are effective and safe for treating alopecia, but more research is needed.
September 2025 in “Dermatology and Therapy” The treatment improved hair growth and was well-received without side effects.
3 citations
,
January 1992 in “Gynecological Endocrinology” 3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.